← All stocks

Maze Therapeutics, Inc.

MAZE Net selling
CIK 0001842295 #2211 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$2.93M
$254.50K on a plan · $1.54M straight out of an exercise
Sold at will
$1.14M
16 of 21 sales
Net
−$2.93M
−$1.14M against sales at will

By person

10 insiders · 21 transactions

There is no salary here to measure against. Maze Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Coloma Jason V
Chief Executive Officer
$1.50M (6) scheduled
−$1.50M
524,131
0.9435%
$13.74M
−21.7%
Bernstein Harold
President, R&D & CMO
$950.13K (6) scheduled
−$950.13K
0
0.0000%
$0.00
Dandekar Atul
CSBO
$375.63K (5) scheduled
−$375.63K
32,316
0.0582%
$847.45K
+170.5%
Courtney Phillips
GC and Corp. Secretary
$104.77K (4)
−$104.77K
7,007
0.0126%
$183.75K
Third Rock Ventures IV, L.P. entity
10% owner
5,424,758
9.77%
$142.26M
+1,643%
Lim Jonathan E
Director
307,956
0.5544%
$8.08M
HOMCY CHARLES J
Director
38,535
0.0694%
$1.01M
+7.2%
Bachrodt Amy
SVP, Finance
12,965
0.0233%
$339.99K
0.0%
SCHELLER RICHARD H
Director
0
0.0000%
$0.00
−100.0%
Sohn Catherine A.
Director
0
0.0000%
$0.00
Insider
Date
Role
Action
Shares
Price
Amount
Bernstein Harold
4 Sep 2026
President, R&D & CMO
Sold on a plan
9,705
$26.22
$254.50K

What was left out

Form 4 filings counted 12
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 1
Sales straight out of an exercise 4
Sales at will 16
Transactions with no price 0
Shares from compensation/vesting 117,141
History held since 4 Feb 2025